BR112013005049A2 - estabilizador para a preparação de uma composição vacina da pólio seca injetável - Google Patents

estabilizador para a preparação de uma composição vacina da pólio seca injetável

Info

Publication number
BR112013005049A2
BR112013005049A2 BR112013005049A BR112013005049A BR112013005049A2 BR 112013005049 A2 BR112013005049 A2 BR 112013005049A2 BR 112013005049 A BR112013005049 A BR 112013005049A BR 112013005049 A BR112013005049 A BR 112013005049A BR 112013005049 A2 BR112013005049 A2 BR 112013005049A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
preparation
dry
stabilizer
injectable
Prior art date
Application number
BR112013005049A
Other languages
English (en)
Inventor
Alain Francon
Amandine Leleu
Pierre Chouvenc
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of BR112013005049A2 publication Critical patent/BR112013005049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

estabilizador para a preparação de uma composição vacina da pólio seca injetável. a presente invenção refere-se a um agente estabilizar, uma composição de vacina estabilizada aquosa injetável e um processo para a preparação de uma composição de vacina seca, permitindo que o antígeno de pólio ipv venha a ser seco sem uma grande perda de titulação durante o processo de secagem e permitindo que o produto seco venha a ser armazenado sem uma grande perda de titulação de pelo menos 7 dias a 37<198>c e uma composição de vacina estabilizada seca compreendendo um poliovírus inativado (ipv), pelo menos, um sorótipo, caracterizado por meio de uma estabilidade térmica excepcional.
BR112013005049A 2010-09-02 2011-08-31 estabilizador para a preparação de uma composição vacina da pólio seca injetável BR112013005049A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1056961 2010-09-02
PCT/EP2011/004394 WO2012028315A1 (en) 2010-09-02 2011-08-31 A stabilizer for the preparation of a dry polio injectable vaccine composition

Publications (1)

Publication Number Publication Date
BR112013005049A2 true BR112013005049A2 (pt) 2016-05-31

Family

ID=43858132

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005049A BR112013005049A2 (pt) 2010-09-02 2011-08-31 estabilizador para a preparação de uma composição vacina da pólio seca injetável

Country Status (2)

Country Link
BR (1) BR112013005049A2 (pt)
WO (1) WO2012028315A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2971068T3 (da) 2013-03-14 2020-01-27 Siemens Healthcare Diagnostics Inc Styring af ph i vandige urinstofholdige opløsninger ved anvendelse af aminosyreholdige sammensætninger
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
KR102012558B1 (ko) * 2017-09-20 2019-08-20 사단법인대한결핵협회 결핵 진단용 항원 안정화 조성물 및 결핵 진단 방법
CN108241058A (zh) * 2018-01-13 2018-07-03 中国医学科学院医学生物学研究所 一种脊髓灰质炎病毒ⅲ型d抗原预包被检测方法及其检测试剂盒和应用
CN108387726A (zh) * 2018-01-13 2018-08-10 中国医学科学院医学生物学研究所 脊髓灰质炎病毒ⅰ、ⅱ、ⅲ型d抗原同步快速鉴别、定量检测方法及其检测试剂盒和应用
CN108287237A (zh) * 2018-01-13 2018-07-17 中国医学科学院医学生物学研究所 一种脊髓灰质炎病毒ⅱ型d抗原预包被检测方法及其检测试剂盒和应用
US11911457B2 (en) * 2018-02-07 2024-02-27 Bharat Biotech International Limited Process for enterovirus purification and inactivation and vaccine compositions obtained thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
FR2633518B1 (fr) * 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
DK1133316T3 (da) * 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
ES2645924T3 (es) 2002-11-01 2017-12-11 Glaxosmithkline Biologicals S.A. Procedimiento de secado
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Also Published As

Publication number Publication date
WO2012028315A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
BR112013005049A2 (pt) estabilizador para a preparação de uma composição vacina da pólio seca injetável
AR118273A2 (es) Excipiente estabilizante para una vacuna de virus completo inactivado
BR112015015031A2 (pt) processo de glicoconjugação
AR118582A2 (es) Procedimiento para producir sílice precipitada tratada
BR112015018493A2 (pt) Linhagens celulares para produção de vírus e métodos de uso
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
BR112016028937A2 (pt) método de uso da composição compreendendo um composto de amônio quaternário, um polissacarídeo catiônico e um polissacarídeo não iônico
BR112014020930A2 (pt) método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
UY35567A (es) ?derivados de 3-((2s,5s)-4-metilen-5-(3- oxopropil)tetrahidrofuran-2-il)propanol, su preparación e intermediarios útiles para la misma?.
BR112018013174B8 (pt) Composição e método para crescimento de cabelo
UY36897A (es) Composiciones inoculantes estables y métodos para su producción
WO2015002729A3 (en) Cell stabilization
EA200970844A1 (ru) Способы изготовления восстановленных табачных листов
BR112017005780A2 (pt) ?uso de um carbonato de cálcio reagido na superfície como agente antiaglomerante, métodos para controlar, reduzir ou evitar aglomeração de uma composição particulada e para produzir uma composição, e, composição?
CR20180503A (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112015032346A2 (pt) compostos de isotiazolina para o combate de pragas de invertebrados
NO20091530L (no) Fenylalkylaminokarbamat preparater
BR112016006335A2 (pt) macarrão instantâneo seco e método de produção para o mesmo
BR112018006519A2 (pt) compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente
BR112018010499A2 (pt) método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células
BR112016029158A2 (pt) composições de álcool poli-hídrico para desidratação de gás
AR074808A1 (es) Un proceso para fabricar papel
CL2011002618A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas; composición farmacéutica que los comprende; y uso del compuesto o de la composición como moduladores de ccr3 para prevenir o tratar una enfermedad inflamatoria tal como asma, asma inducido por ejercicio, rinitis alérgica, dermatitis atópica, conjuntivitis alérgica o enfermedad obstructiva crónica.
AR075308A1 (es) Composicion para controlar fitoenfermedades y metodo para controlar fitoenfermedades

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B25D Requested change of name of applicant approved

Owner name: SANOFI PASTEUR SA (FR)

B25G Requested change of headquarter approved

Owner name: SANOFI PASTEUR SA (FR)

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements